Current Oncology, Volume 25, Issue 5

Once, I was invited to give a lecture to undergraduate medical students during their cancer biology course. [...]

Background: Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Re...

Introduction: Patients with cancer of unknown primary (CUP) have pathologically confirmed metastatic tumours with unidentifiable primary tumours. Currently, very little is known about the relationship between the treatment of patients with CUP and th...

Background: Inhibition of the anaplastic lymphoma kinase (ALK) oncogenic driver in advanced non-small-cell lung carcinoma (NSCLS) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the identificat...

Management of anticoagulant therapy for the treatment of venous thromboembolism (VTE) in cancer patients is complex because of an increased risk of recurrent VTE and major bleeding complications in those patients relative to the general population. S...

Background: Cancer research is essential in evaluating the safety and effectiveness of emerging cancer treatments, which in turn can lead to ground-breaking advancements in cancer care. Given limited research funding, allocating resources in alignmen...

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as monotherapy or combination therapy have emerged as effective treatment options for immune-sensitive solid tumours and hematologic malignancies. The benefits o...

Introduction: Neuroendocrine tumours (NETS) are a poorly understood malignancy lacking standardized care. Differences in socioeconomic status (SES) might worsen the effect of non-standardized care. We examined the effect of SES on NET peri-diagnostic...

Background: Up to 90% of breast cancer survivors report low levels of physical activity (PA) and spend approximately 70% of the day in sedentary behaviour. Survivors might not be receiving information about the health benefits of PA and the consequen...

Immunotherapy has emerged as a new standard of care, showing survival benefit for solid tumours in multiple disease sites and indications. The survival improvements seen in diseases that were highly resistant to traditional therapies, with a poor pro...